25.16
0.10 (0.40%)
| Previous Close | 25.06 |
| Open | 25.06 |
| Volume | 511,876 |
| Avg. Volume (3M) | 1,884,698 |
| Market Cap | 4,244,793,856 |
| Price / Earnings (TTM) | 18.92 |
| Price / Earnings (Forward) | 54.95 |
| Price / Sales | 4.16 |
| Price / Book | 5.20 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | 22.97% |
| Operating Margin (TTM) | 7.90% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 18.70% |
| Quarterly Earnings Growth (YOY) | 14.70% |
| Total Debt/Equity (MRQ) | 7.32% |
| Current Ratio (MRQ) | 2.88 |
| Operating Cash Flow (TTM) | 148.96 M |
| Levered Free Cash Flow (TTM) | 19.27 M |
| Return on Assets (TTM) | 5.56% |
| Return on Equity (TTM) | 37.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ACADIA Pharmaceuticals Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.57% |
| % Held by Institutions | 104.46% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (RBC Capital, 58.98%) | Buy |
| Median | 30.50 (21.22%) | |
| Low | 17.00 (Goldman Sachs, -32.43%) | Sell |
| Average | 29.36 (16.69%) | |
| Total | 9 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 22.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 08 Aug 2025 | 36.00 (43.08%) | Buy | 24.60 |
| Goldman Sachs | 07 Aug 2025 | 17.00 (-32.43%) | Sell | 24.40 |
| JMP Securities | 07 Aug 2025 | 35.00 (39.11%) | Buy | 24.40 |
| 26 Jun 2025 | 37.00 (47.06%) | Buy | 22.21 | |
| Mizuho | 07 Aug 2025 | 24.00 (-4.61%) | Hold | 24.40 |
| 19 May 2025 | 23.00 (-8.59%) | Hold | 21.99 | |
| RBC Capital | 07 Aug 2025 | 40.00 (58.98%) | Buy | 24.40 |
| 23 Jun 2025 | 38.00 (51.03%) | Buy | 22.48 | |
| JP Morgan | 24 Jul 2025 | 34.00 (35.14%) | Buy | 23.05 |
| 06 Jun 2025 | 30.00 (19.24%) | Buy | 21.98 | |
| HC Wainwright & Co. | 26 Jun 2025 | 32.00 (27.19%) | Buy | 22.21 |
| 19 May 2025 | 32.00 (27.19%) | Buy | 21.99 | |
| Needham | 26 Jun 2025 | 30.00 (19.24%) | Buy | 22.21 |
| 19 May 2025 | 30.00 (19.24%) | Buy | 21.99 | |
| Oppenheimer | 26 Jun 2025 | 22.00 (-12.56%) | Hold | 22.21 |
| B of A Securities | 05 Jun 2025 | 23.00 (-8.59%) | Hold | 21.34 |
| Deutsche Bank | 21 May 2025 | 35.00 (39.11%) | Buy | 21.85 |
| Morgan Stanley | 20 May 2025 | 24.00 (-4.61%) | Hold | 21.69 |
| BMO Capital | 19 May 2025 | 28.00 (11.29%) | Buy | 21.99 |
| Baird | 19 May 2025 | 31.00 (23.21%) | Buy | 21.99 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |